TY - JOUR
T1 - Early esophageal cancer specific survival is unaffected by anatomical location of tumor
T2 - A population-based study
AU - Amin, Rajan N.
AU - Parikh, Samip J.
AU - Gangireddy, Venu Gopala Reddy
AU - Kanneganti, Praveen
AU - Talla, Swathi
AU - Daram, Sumanth Reddy
N1 - Publisher Copyright:
© 2016 Rajan N. Amin et al.
PY - 2016
Y1 - 2016
N2 - Background. Approximately one-fifth of all esophageal cancer cases are defined as early esophageal cancer (EEC). Although endoscopic therapy (ET) has been shown to be equally effective as esophagectomy (EST) in patients with EEC, there is little information comparing the survival outcomes of the two therapies based on anatomical location. Methods. A population-based study was conducted and the data was obtained from Surveillance, Epidemiology, and End Results program. Patients with EEC (i.e., stages Tis and T1a) and treated with either ET or EST were analyzed to compare EEC-related survival for three different locations of tumor. Results. The overall EEC-specific 1-year and 5-year mean (±SE) survival rates were 11.66 ± 0.0 5 and 52.80 ± 0.5 8 months, respectively. Tumors located in lower third had better 5-year survival compared to those located in middle third (83.50% versus 73.10%, p < 0.01). However, when adjusted for age, race, gender, marital status, grade, stage of tumor, histological type, and treatment modality, there was no significant difference. Conclusion. The EEC-specific 1-year or 5-year adjusted survival did not differ by anatomic location of the tumor. Therefore, ET might serve as a minimally invasive yet effective alternative to EST to treat EEC.
AB - Background. Approximately one-fifth of all esophageal cancer cases are defined as early esophageal cancer (EEC). Although endoscopic therapy (ET) has been shown to be equally effective as esophagectomy (EST) in patients with EEC, there is little information comparing the survival outcomes of the two therapies based on anatomical location. Methods. A population-based study was conducted and the data was obtained from Surveillance, Epidemiology, and End Results program. Patients with EEC (i.e., stages Tis and T1a) and treated with either ET or EST were analyzed to compare EEC-related survival for three different locations of tumor. Results. The overall EEC-specific 1-year and 5-year mean (±SE) survival rates were 11.66 ± 0.0 5 and 52.80 ± 0.5 8 months, respectively. Tumors located in lower third had better 5-year survival compared to those located in middle third (83.50% versus 73.10%, p < 0.01). However, when adjusted for age, race, gender, marital status, grade, stage of tumor, histological type, and treatment modality, there was no significant difference. Conclusion. The EEC-specific 1-year or 5-year adjusted survival did not differ by anatomic location of the tumor. Therefore, ET might serve as a minimally invasive yet effective alternative to EST to treat EEC.
UR - http://www.scopus.com/inward/record.url?scp=84985918299&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84985918299&partnerID=8YFLogxK
U2 - 10.1155/2016/6132640
DO - 10.1155/2016/6132640
M3 - Article
C2 - 27559535
AN - SCOPUS:84985918299
SN - 2291-2789
VL - 2016
JO - Canadian Journal of Gastroenterology and Hepatology
JF - Canadian Journal of Gastroenterology and Hepatology
M1 - 6132640
ER -
